The author suggests investors can still get into MAIA before the interim data readout, implying the catalyst is the upcoming interim data for this Phase 3 oncology company. The mechanism is that positive interim data would re-rate the stock, and entering before it captures that move. No specific risk or timeframe is stated beyond the interim data event.